Diabetes

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and accessibility. What’s keeping the pills from taking off?

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority of people who use these drugs quit after just two years

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects

Researchers combined the drug harmine with a medication similar to Ozempic to boost the number and function of human insulin-producing cells transplanted into mice

Ozempic, Wegovy and other GLP-1 drugs are being investigated as treatments for many health conditions—from dementia to addiction to kidney problems

The neurons that produce a sick feeling and food aversion are distinct from those that induce a feeling of fullness

Brain waves during sleep influence glucose and insulin, offering new insights into controlling diabetes

Limited data on adults age 60 and older raise questions on whether high-priced weight-loss drugs will really help with lowering rates of chronic illness and disability

United Nations groups say the artificial sweetener poses a possible risk of liver cancer—but there’s no evidence for harm under the current daily limit

New types of cutlery can enhance flavors such as sweetness or saltiness for a more satisfying meal

Thanks to huge advancements in technology to monitor and treat type 1 diabetes, families like mine can sleep throughout the night